Aflibercept for the treatment of diabetic macular edema

Keegan A. Harkins, Mary Haschke, Diana V. Do

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.

Original languageEnglish (US)
Pages (from-to)503-510
Number of pages8
Issue number5
StatePublished - May 2016


  • Aflibercept
  • anti-VEGF
  • antiangiogenesis
  • diabetic macular edema
  • diabetic retinopathy
  • placental growth factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Aflibercept for the treatment of diabetic macular edema'. Together they form a unique fingerprint.

Cite this